Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Despite So-So Sales To Date, HGS Sees Promising Launch For Benlysta

This article was originally published in The Pink Sheet Daily

Executive Summary

Third quarter U.S. sales of $18.8 million disappoint some analysts, but HGS emphasizes growing patient base and multi-part commercialization plan still being implemented.

You may also be interested in...

HGS Calls For Confidence In Slow, Steady Ramp-Up For Benlysta

In the fourth quarter, the new SLE drug continued its slow sales growth – HGS said rheumatologists are still largely in trial mode, testing the drug in a few patients and gaining confidence in its benefits.

GSK Gears Up To Fight NICE On Benlysta Setback

In preliminary assessment, NICE says it won't recommend GSK's Benlysta for systemic lupus erythematosus as it is too expensive, but a population subgroup analysis may be able to change the ruling.

HGSI/GSK's Benlysta Gets BLySfully Clean Labeling, Escaping Feared Restrictions

The indication is notable for what it does not contain, which is language specifically excluding African Americans or patients with severe active lupus nephritis or severe central nervous system lupus.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts